607
Participants
Start Date
December 6, 2017
Primary Completion Date
November 7, 2024
Study Completion Date
November 7, 2024
BMS-986249
Specified dose on specified days
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Local Institution - 0038, Buenos Aires
Local Institution - 0015, North Sydney
Local Institution - 0047, Heidelberg
Local Institution - 0025, Frankston
Local Institution - 0014, Adelaide
Local Institution - 0002, New York
Local Institution - 0003, New York
Local Institution - 0004, Philadelphia
Local Institution - 0048, Milan
Local Institution - 0012, Leesburg
Local Institution - 0035, Hamburg
Local Institution - 0024, Baltimore
Local Institution - 0007, Norfolk
Local Institution - 0022, Madrid
Local Institution - 0023, Madrid
Local Institution - 0050, Madrid
Local Institution - 0043, Málaga
Local Institution - 0008, Greenville
Local Institution - 0017, Miami
Local Institution - 0030, Essen
Local Institution - 0029, Cincinnati
Local Institution - 0049, Siena
Local Institution - 0031, Heidelberg
Local Institution - 0009, Dallas
Local Institution - 0011, Tyler
Local Institution - 0021, Houston
Local Institution - 0016, San Antonio
Local Institution - 0005, Aurora
Local Institution - 0020, Napoli
Local Institution - 0006, Denver
Local Institution - 0013, Eugene
Local Institution - 0018, Vancouver
Local Institution - 0041, Craiova
Local Institution - 0036, Santiago
Local Institution - 0001, Hackensack
Local Institution - 0010, Austin
Local Institution - 0052, CABA
Local Institution - 0037, Buenos Aires
Local Institution - 0026, Edmonton
Local Institution - 0056, Ottawa
Local Institution - 0039, Helsinki
Local Institution - 0040, Warsaw
Local Institution - 0045, Bucharest
Local Institution - 0042, Badalona
Local Institution - 0044, Barcelona
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY